Table 2. Associations between MSS of CM patients and selected SNPs of the PDGF pathway in the MDACC study.
| Genotype | Frequency | Death (%) | Univariate analysis | Multivariate analysis* | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| NCK2 | ||||||
| rs6707820 C>T (genotyped) | ||||||
| CC | 644 | 64 (9.9) | 1.00 | 1.00 | ||
| CT | 204 | 27 (13.2) | 1.39 (0.89-2.18) | 0.153 | 1.87 (1.16-2.99) | 0.010 |
| TT | 10 | 4 (40.0) | 4.99 (1.82-13.71) | 0.002 | 6.58 (2.29-18.90) | 0.001 |
| Trend test | 0.012 | <0.001 | ||||
| CT+TT | 214 | 31 (14.5) | 1.53 (1.00-2.35) | 0.052 | 2.05 (1.31-3.22) | 0.002 |
| PRKCD | ||||||
| rs2306574 T>C (imputed) | ||||||
| TT | 534 | 45 (8.4) | 1.00 | 1.00 | ||
| CT | 283 | 39 (13.8) | 1.70 (1.11-2.61) | 0.016 | 1.68 (1.07-2.63) | 0.023 |
| CC | 41 | 11 (26.8) | 3.92 (2.03-7.59) | <0.001 | 4.45 (2.26-8.74) | <0.001 |
| Trend test | <0.001 | <0.001 | ||||
| CT+CC | 324 | 50 (15.4) | 1.94 (1.30-2.90) | 0.001 | 1.97 (1.30-2.99) | 0.001 |
MSS: melanoma-specific survival; CM: cutaneous melanoma; SNP: single nucleotide polymorphism; MDACC: The University of Texas M.D. Anderson cancer center; HR: hazards ratio; CI: confidence interval.
* Adjusted for age, sex, Breslow thickness, regional/distant metastasis, ulceration, mitotic rate of tumors.